The FDA approved an mRNA-based influenza vaccine mFLUSIVA for adults aged 50 years and older, with accelerated approval applying to adults aged 65 years and older.
New influenza and RSV research offers clinically relevant insights into vaccine performance and outbreak prevention. This roundup examines an investigational mRNA flu vaccine, rapid oseltamivir use in...
A real-world analysis found that mRNA SARS-CoV-2 vaccination was associated with lower 3-year mortality after CAR T-cell therapy in patients with hematologic malignancies.
The FDA approved ensitrelvir (Xocova) for post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older following contact with an individual with COVID-19.
ACOG’s 2026 maternal immunization schedule outlines vaccine recommendations before, during, and after pregnancy, including influenza, COVID-19, Tdap, and RSV vaccination.
As HPV-vaccinated cohorts age into screening eligibility, researchers evaluated how cervical cancer screening intensity could be tailored by age at vaccination and vaccine type to balance benefits, harms,...
Recent studies in children and adults associate long COVID with worsened academic performance, attention difficulties, subjective cognitive impairment, and persistent neurologic and psychiatric symptoms.
...
